A high incidence of Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) was seen in adults with B-cell ALL in a study involving 148 individuals. Moreover, outcomes were substantially worse in a subset of patients with cytokine receptor-like factor 2 (CRLF2).
Participants—all of whom had newly diagnosed B-cell ALL and received frontline chemotherapy—underwent gene expression profiling of leukemic cells. One-third had Ph-like, 31% had Ph+, and 36% had other subtypes. Among the results:
- 6 in every 10 patients with Ph-like ALL had CRLF2 overexpression.
- 5-year survival rate in patients with Ph-like ALL was 23%, vs 59% in those with other subtypes.
- ~Two-thirds of Ph-like ALL patients were Hispanic.
- Age, white blood cell count, platelet count, and Ph-like ALL were linked with inferior overall survival.
- JAK2 mutation was linked with inferior outcomes in the CRLF2+ group.
Jain N, Roberts K, Jabbour E, et al. Ph-like acute lymphoblastic leukemia: A high-risk subtype in adults. Blood. 2017;129(5):572-581. doi:10.1182/blood-2016-07-726588.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al